## Guglielmo Rosario Domenico Villani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/682930/publications.pdf

Version: 2024-02-01

34 papers

974 citations

394421 19 h-index 31 g-index

34 all docs 34 docs citations

34 times ranked 1254 citing authors

#	Article	IF	Citations
1	Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. Journal of Neuroscience Research, 2007, 85, 612-622.	2.9	106
2	Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism. Molecular BioSystems, 2015, 11, 1525-1535.	2.9	73
3	Gene Therapy for a Mucopolysaccharidosis Type I Murine Model with Lentiviral-IDUA Vector. Human Gene Therapy, 2005, 16, 81-90.	2.7	72
4	"Classical organic acidurias― diagnosis and pathogenesis. Clinical and Experimental Medicine, 2017, 17, 305-323.	3.6	69
5	Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector. Biochemical Journal, 2005, 388, 639-646.	3.7	56
6	Mucopolysaccharidosis IIIB: Oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Research, 2009, 1279, 99-108.	2.2	53
7	Maternal vitamin B12 deficiency detected in expanded newborn screening. Clinical Biochemistry, 2014, 47, 312-317.	1.9	53
8	Heparan N-sulfatase gene: two novel mutations and transient expression of 15 defects. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1501, 1-11.	3.8	37
9	Mutations among Italian mucopolysaccharidosis type I patients. Journal of Inherited Metabolic Disease, 1997, 20, 803-806.	3.6	34
10	Influence of Sex on Urinary Organic Acids: A Cross-Sectional Study in Children. International Journal of Molecular Sciences, 2020, 21, 582.	4.1	33
11	Intracranial gene delivery of LVâ€NAGLU vector corrects neuropathology in murine MPS IIIB. American Journal of Medical Genetics, Part A, 2009, 149A, 1209-1218.	1.2	32
12	Effect of avarol and avarone on in vitro-induced microsomal lipid peroxidation. Toxicology, 1992, 72, 221-233.	4.2	31
13	Molecular defects in the α-N-acetylglucosaminidase gene in Italian Sanfilippo type B patients. Human Genetics, 2000, 107, 568-576.	3.8	30
14	Maroteaux–Lamy syndrome: five novel mutations and their structural localization. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1453, 185-192.	3.8	25
15	Hurler Disease Bone Marrow Stromal Cells Exhibit Altered Ability to Support Osteoclast Formation. Stem Cells and Development, 2012, 21, 1466-1477.	2.1	24
16	Insulinâ€resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria?. Journal of Inherited Metabolic Disease, 2018, 41, 985-995.	3.6	24
17	Expression of five iduronate-2-sulfatase site-directed mutations. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1501, 71-80.	3.8	20
18	Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer. Biochemical Journal, 2002, 364, 747-753.	3.7	20

#	Article	IF	CITATIONS
19	An adult Sanfilippo type A patient with homozygous mutation R206P in the sulfamidase gene. American Journal of Medical Genetics, Part A, 2005, 133A, 85-89.	1.2	20
20	Molecular analysis of DNA adducts and hprt mutations produced by 6-nitrosochrysene in Chinese hamster ovary cells. Carcinogenesis, 1993, 14, 1863-1870.	2.8	18
21	Analysis of Sanfilippo A gene mutations in a large pedigree. Clinical Genetics, 2003, 63, 314-318.	2.0	18
22	Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis typeÂVI disease. Biotechnology and Applied Biochemistry, 2008, 49, 219.	3.1	18
23	Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1588, 203-209.	3.8	17
24	The effect of four mutations on the expression of iduronate-2-sulfatase in mucopolysaccharidosis type II. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2001, 1537, 233-238.	3.8	16
25	In vitrogene therapy of mucopolysaccharidosis type I by lentiviral vectors. FEBS Journal, 2002, 269, 2764-2771.	0.2	15
26	Unfolded protein response is not activated in the mucopolysaccharidoses but protein disulfide isomerase 5 is deregulated. Journal of Inherited Metabolic Disease, 2012, 35, 479-493.	3.6	13
27	Enhancement of tissue lipoperoxidation in propanil-treated rats. Toxicology Letters, 1995, 78, 215-218.	0.8	12
28	Large Deletion Involving Exon 5 of the Arylsulfatase B Gene Caused Apparent Homozygosity in a Mucopolysaccharidosis Type VI Patient. Genetic Testing and Molecular Biomarkers, 2010, 14, 113-120.	0.7	10
29	Prenatal diagnosis of Sanfilippo type A syndrome in a family with S66W mutant allele. , 1999, 19, 993-994.		8
30	Biochemical and molecular characterization of 3-Methylcrotonylglycinuria in an Italian asymptomatic girl. Genetics and Molecular Biology, 2018, 41, 379-385.	1.3	8
31	Extraneurologic symptoms as presenting signs of Sanfilippo disease. Pediatric Neurology, 2001, 25, 254-257.	2.1	4
32	Hypermethioninemia in Campania: Results from 10†years of newborn screening. Molecular Genetics and Metabolism Reports, 2019, 21, 100520.	1.1	2
33	A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency. Journal of Nephrology, 2012, 25, 582-585.	2.0	2
34	Effect of rat liver cytosolic enzymes and cofactors on mutagenicity of 1-amino-8-nitropyrene. Carcinogenesis, 1991, 12, 361-364.	2.8	1